<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="0" ids="28783">Zinc protoporphyrin</z:chebi> (ZnPP) has multiple actions </plain></SENT>
<SENT sid="1" pm="."><plain>It is an interleukin-1 antagonist as well as a hemeoxygenase inhibitor </plain></SENT>
<SENT sid="2" pm="."><plain>Interleukin-1 is produced in ischemic brain and probably contributes to ischemic injury, although the role of <z:chebi fb="4" ids="30413">heme</z:chebi> oxygenase during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> is unknown </plain></SENT>
<SENT sid="3" pm="."><plain>Whether ZnPP treatment is more effective before or after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, as well as whether it is more protective in permanent or temporary <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, is also unknown </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, we investigated the effect of ZnPP on infarction size and <z:hpo ids='HP_0000969'>edema</z:hpo> in a <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of temporary and permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: Two groups of adult male Sprague-Dawley rats were pretreated with either 50 mg/kg ZnPP IP or saline and subjected to permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> 30 minutes later </plain></SENT>
<SENT sid="6" pm="."><plain>Four additional groups of animals were subjected to 2 hours of temporary middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 22 hours of reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>Two of these groups were pretreated 30 minutes before middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> with either 50 mg/kg ZnPP IP or saline </plain></SENT>
<SENT sid="8" pm="."><plain>The other groups received ZnPP at either 2 or 4 hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Regional cerebral blood flow in the ischemic cortex was monitored with laser Doppler flowmetry </plain></SENT>
<SENT sid="10" pm="."><plain>Cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> size and brain water were measured 24 hours after the <z:hpo ids='HP_0003674'>onset</z:hpo> of either form of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>RESULTS: Regional cerebral blood flow after occlusion was approximately 13% to 20% of baseline after either permanent or temporary <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>ZnPP had no effect on regional cerebral blood flow, <z:mpath ids='MPATH_124'>infarct</z:mpath> size, or <z:hpo ids='HP_0000969'>edema</z:hpo> formation in permanent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>In contrast, pretreatment significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size (17.2 +/- 6.6% in controls versus 6.2 +/- 2.9% in pretreated rats) and <z:hpo ids='HP_0000969'>edema</z:hpo> formation (center zone, 4.00 +/- 0.71% water in controls versus 1.18 +/- 0.26% water in pretreated rats) in the model of temporary <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, but treatment after occlusion had no effect </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: ZnPP treatment protected the brain when administered early in the temporary <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> model </plain></SENT>
</text></document>